Bolt Projects Holdings, Inc.
Bolt Projects Holdings, Inc. is a U.S.-based specialty materials company built around its Vegan Silk Technology Platform, which it uses to develop and sell biomaterial products for beauty and personal care applications. The company’s current commercial focus is b-silk, a product positioned as a substitute for silicone elastomers in formulations. Bolt also previously worked on Mylo, a mycelium-based leather alternative, but discontinued that program in early 2023 to concentrate on Vegan Silk commercialization. Following a 2024 reverse merger, the operating business of Bolt Threads became the business of Bolt Projects Holdings, Inc., and the company now trades on Nasdaq under the ticker BSLK.
Fiscal year 2024 · change from previous year
Development 2021–2024
Business
Share of revenueFinished products sold to customers, primarily b-silk derived from the Vegan Silk Technology Platform.
Internal R&D and product development work to extend the Vegan Silk platform into new applications.
Production, warehousing, packaging, and shipping activities supporting product delivery.
Customers
Bolt sells primarily into the beauty and personal care market, where formulators use b-silk as an ingredient substitute for silicone elastomers. The company indicates that customer awareness and experience with its products remain limited, which means adoption depends on proving performance, quality, and price competitiveness. Its buyers are likely ingredient customers, brand owners, and formulation partners that need novel sensory or functional materials for cosmetics and personal care products. Because Bolt is still early in commercialization, retaining existing customers and winning new ones are central to revenue growth. The company’s decision to discontinue Mylo also suggests it is concentrating resources on the customer segment with the clearest near-term commercial path.
They buy b-silk to improve texture, feel, and formulation performance while replacing silicone elastomers.
They use Bolt’s materials through finished formulations to support product differentiation and vegan/clean-label positioning.
They help place the product into formulations and broaden market access for the Vegan Silk platform.
They may adopt future products from the platform if Bolt expands beyond b-silk into new applications.
Strategy
Bolt’s strategy is to focus resources on the Vegan Silk Technology Platform and commercialize b-silk rather than spread capital across multiple experimental programs. Management has explicitly said it discontinued Mylo to concentrate on the platform with the clearest commercialization path. The company is also investing in R&D, product development, and expanded fermentation capacity with manufacturing partners to support future growth. Because it is in a growth stage and has limited operating history, Bolt’s strategy also includes raising additional capital when needed to fund working capital, product expansion, and market development. Maintaining Nasdaq compliance and operating as a public company are now part of the execution burden and capital strategy.
It is the company’s principal revenue source and the clearest path to scaling sales.
Platform innovation is needed to maintain differentiation and create follow-on products.
The company relies on a single manufacturing partner, so continuity of supply is critical.
The business is growth-stage and may need external financing while managing Nasdaq requirements.
Geography
The available filings do not disclose a country-by-country revenue split, so Bolt’s geographic profile must be inferred from its U.S. domicile and operating structure. The company is headquartered in the United States and trades on Nasdaq, which makes U.S. capital markets and regulatory compliance important to the business. Its manufacturing is outsourced to Laurus Bio, so operational geography depends on that partner’s production footprint rather than Bolt-owned plants. Because the company is still early in commercialization, geography matters more through supply-chain reliability, customer access, and public-market listing requirements than through a broad international footprint. No authoritative regional revenue breakdown was provided in the excerpts.
Risks
Bolt’s biggest company-specific risk is concentration: substantially all revenue currently comes from b-silk, so any product, customer, or market setback would have an outsized effect on results. The company also depends on a single manufacturing partner, Laurus Bio, which creates supply-chain and continuity risk if that relationship is disrupted. Nasdaq has already notified Bolt of listing compliance issues, so delisting risk could reduce liquidity and make future capital raising more difficult. More broadly, the company faces the usual risks of an early-stage specialty materials business, including uncertain customer adoption, pricing pressure, and the possibility that R&D spending does not produce commercially successful products. Because Bolt is still building its commercial base, its operating results are likely to remain volatile and sensitive to financing conditions.
- Nasdaq delisting or continued listing non-complianceImpact: HighLikelihood: High
The company received Nasdaq notices regarding market value and equity standards, which can affect liquidity and capital access.
Exposure: Capital markets
- Product concentration in b-silkImpact: High
Substantially all revenue is derived from one product platform, so demand weakness would directly hit sales.
Exposure: Revenue and growth
- Single manufacturing partner dependencyImpact: High
The company relies on Laurus Bio to produce Vegan Silk products, so any disruption could impair supply.
Exposure: Operations and fulfillment
- Funding and dilution riskImpact: MediumLikelihood: High
Growth-stage operations and expansion plans may require additional equity or debt financing.
Exposure: Balance sheet and ownership dilution
- Customer adoption uncertaintyImpact: Medium
The company says awareness and experience with its products are limited, making demand hard to predict.
Exposure: Commercialization
Accounting
Judgemental itemsSales are recorded when control transfers at shipment, so order timing and logistics affect reported revenue.
Impact: Quarterly revenue volatility and cut-off risk
Cost of revenue includes warehousing, shipping, quality assessments, and inventory impairment.
Impact: Gross loss and margin volatility
Public-company and growth-stage compensation can be a significant non-cash expense.
Impact: Operating expense burden and diluted earnings
The post-merger financial statements reflect the accounting acquirer’s historical results, affecting comparability.
Impact: Period-to-period comparability
Similar listed companies
Publicly listed companies with a comparable business focus.
Bolt Biotherapeutics, Inc.
BOLT · Pharmaceutical Preparations
KULR Technology Group, Inc.
KULR · Electronic Components & Accessories
Charlie's Holdings, Inc.
CHUC · Medicinal Chemicals & Botanical Products
Abpro Holdings, Inc.
ABPWW · Biological Products, (No Diagnostic Substances)
Krystal Biotech, Inc.
KRYS · Biological Products, (No Diagnostic Substances)
Krystal Biotech is a commercial-stage biotechnology company that develops and sells genetic medicines built on an engineered HSV-1 gene therapy platform.
Biofrontera Inc.
BFRIW · Pharmaceutical Preparations
Last updated: 24/09/2026